Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same

Abstract

The present invention relates to a modified taurine, and a pharmaceutical composition for preventing or treating metabolic disease or a food composition, which contains the modified taurine as an active ingredient. More specifically, the modified taurine of the present invention has physical properties different from those of existing taurine, and has significant effects on the prevention and treatment of metabolic syndrome, including antithrombotic effects.

1 . A modified taurine produced by dissolving taurine with heating in a first polar solvent and adding a second polar solvent thereto,
 wherein a difference in polarity between the first polar solvent and the second polar solvent is 5 or less, and wherein the ratios of absorption bands of 847/891, 1182/1256 and 1427/1458 at 847, 891, 1182, 1256, 1427 and 1458 cm −1  in the Raman spectrum of the modified taurine are all less than 1.   
     
     
         2 . The modified taurine of  claim 1 , wherein an onset point where the modified taurine starts to melt ranges from 330° C. to 340° C. 
     
     
         3 . The modified taurine of  claim 1 , wherein the modified taurine has a water solubility of 75-79 g/L. 
     
     
         4 . The modified taurine of  claim 1 , wherein the absorption wavelength at 1650-2800 cm −1  in the FT-IR spectrum of the modified taurine differs from that of the taurine. 
     
     
         5 . The modified taurine of  claim 1 , wherein the first polar solvent is water, and the second polar solvent contains a methyl group (—CH 3 ). 
     
     
         6 . The modified taurine of  claim 5 , wherein the second polar solvent is any one or more selected from the group consisting of methanol, ethanol, butanol, acetic acid, acetone, propanol, chloroform, and ethyl acetate. 
     
     
         7 - 16 . (canceled) 
     
     
         17 . A method for producing a modified taurine, comprising the steps of:
 dissolving taurine with heating in a first polar solvent; and adding a second polar solvent thereto to produce the modified taurine,   wherein a difference in polarity between the first polar solvent and the second polar solvent is 5 or less, and wherein the first polar solvent is water, and the second polar solvent contains a methyl group (—CH 3 ).   
     
     
         18 . The method of  claim 17 , wherein the second polar solvent is any one or more selected from the group consisting of methanol, ethanol, butanol, acetic acid, acetone, propanol, chloroform, and ethyl acetate. 
     
     
         19 . The method of  claim 17 , wherein the ratios of absorption bands of 847/891, 1182/1256 and 1427/1458 at 847, 891, 1182, 1256, 1427 and 1458 cm −1  in the Raman spectrum of the modified taurine are all less than 1. 
     
     
         20 . The method of  claim 17 , wherein an onset point where the modified taurine starts to melt ranges from 330° C. to 340° C. 
     
     
         21 . The method of  claim 17 , wherein the modified taurine has a water solubility of 75-79 g/L. 
     
     
         22 . The method of  claim 17 , wherein the absorption wavelength at 1650-2800 cm −1  in the FT-IR spectrum of the modified taurine differs from that of the taurine. 
     
     
         23 . A food composition for improving or alleviating metabolic disease, which contains the modified taurine of  claim 1 .